Brian Nichols

Brian Nichols

InvestorPlace Contributor

Recent Articles

Acadia Pharmaceuticals Inc.: 7 Companies That Could Buy ACAD

By Brian Nichols, InvestorPlace Contributor

Acadia Pharmaceuticals likely has many interested buyers on the line for its drug Nuplazid, which is good news for ACAD stock.

Valeant Pharmaceuticals and LendingClub Have A LOT in Common (NYSE: LC)

By Brian Nichols, InvestorPlace Contributor

LendingClub is not a market favorite right now, but just hang tight, there are more than a few reasons why LC stock will be back on top.

Yahoo! Inc.: Softbank Gives More Bad News to YHOO Stock Owners

By Brian Nichols, InvestorPlace Contributor

Softbank's decision to sell $7.9 billion worth of Alibaba stock has bigger implications for YHOO stock than investors realize.

Valeant Pharmaceuticals Intl Inc: Can Papa’s Lead Save VRX Stock?

By Brian Nichols, InvestorPlace Contributor

Joseph Papa has been unfairly criticized as the new CEO of Valeant (VRX). When you look at his past, it is clear that he is the man for the job.

Michael Kors Holding Ltd: Analysts’ Calls on KORS Stock Conflict

By Brian Nichols, InvestorPlace Contributor

Wedbush and Piper Jaffray on opposite ends of the spectrum when it comes to KORS stock, and ironically, both are probably right.

Load More